ASP7317

· Astellas Institute for Regenerative Medicine

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ASP7317, covering 2026-01-13 to 2026-01-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration [Phase 1]

See pricing